Jean-Luc M. Lemercier - May 7, 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role: CVP, EMEACLA and JAPAC
Signature: Linda J. Park, Attorney-in-Fact
Stock symbol: EW
Transactions as of: May 7, 2023
Transactions value $: -$384,236
Form type: 4
Date filed: 5/9/2023, 07:48 PM
Previous filing: May 4, 2023
Next filing: May 15, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EW	Common Stock	Options Exercise	$0	+3.36K	+1.98%	$0.00	172K	May 7, 2023	Direct	F1
transaction	EW	Common Stock	Tax liability	-$19.9K	-224	-0.13%	$88.74	172K	May 7, 2023	Direct
transaction	EW	Common Stock	Tax liability	-$9.23K	-104	-0.06%	$88.74	172K	May 8, 2023	Direct
transaction	EW	Common Stock	Options Exercise	$234K	+6.64K	+3.86%	$35.20	179K	May 9, 2023	Direct	F2
transaction	EW	Common Stock	Sale	-$589K	-6.64K	-3.72%	$88.68	172K	May 9, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EW	Performance Rights	Options Exercise	$0	-3.36K	-78.48%	$0.00	920	May 7, 2023	Common Stock	3.36K		Direct	F1
transaction	EW	Employee Stock Option (Right to Acquire)	Options Exercise	$0	-6.64K	-100%	$0.00^*	0	May 9, 2023	Common Stock	6.64K	$35.20	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.
F2	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2022.

Content

On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2022.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.